Answers are grounded in this paper and cite their sources.
High-quality evidence on health system barriers and facilitators to adherence to secondary prevention medications for CVD is lacking, especially for low-income settings. Full prescription coverage, reduced copayments, FDC and counselling may be effective in improving adherence and are priorities for further research.
No takes yet. Share an insight, caveat, or question.
Banerjee et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: